BACKGROUND: @entity7730 ( @entity7730 ) is supposed to reduce the risk of micrometastatic progression and improve resectability of @entity1149 ( @entity1149 ). However, best indications for @entity7730 strategy remain unclear in published meta-analyses. Based on this observation, an evaluation of daily practice is of importance. Therefore, we reviewed indications and efficacy time trends in our 30-year series. METHODS: A database including all @entity1 with @entity1149 who underwent surgical resection in two French centers from 1980 to 2009 (n = 5563) was prospectively set and retrospectively reviewed. The indications, clinical and pathologic response rates, and overall survival of @entity7730 @entity1 (n = 732) were analyzed during three successive time-periods: P1 from 1980 to 1989, P2 from 1990 to 1999, and P3 from 2000 to 2009. RESULTS: The proportion of @entity1 who benefited from @entity7730 increased over time, from 2.8% (n = 35) in P1 to 12.5% (n = 274) in P2, and 20.2% (n = 423) in P3. Indications evolved over time with more N2 @entity1 (n = 211; 49.8%) and less initially unresectable @entity1 (n = 72; 17%) in P3. The clinical response rate between @entity3881 increased. Five and 10-year survival rates of @entity7730 @entity1 were 35.2% and 21.5%, respectively. In multivariate analysis, time-period, age, type of resection, histology, and pathologic response to chemotherapy were significant prognostic factors. CONCLUSIONS: Our report on the off-trial use of induction therapy during the last 30 years demonstrates an increased use of @entity7730 , a progressive focus on N2 disease, and improved response rates.

Evolution of induction chemotherapy for XXXX over the last 30 years: A surgical appraisal.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3881 :: ('1423', 'Gene') :: ['P1 and P2'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity7730 :: ('MESH:D064146', 'Disease') :: ['Induction chemotherapy', 'ICT']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
